From April 1, GSK will make price reductions on 110 products and formulations across Least Developed Countries with an average price reduction of 45%, the company announced on 25 March.
It is to reduce prices for patented medicines in the Least Developed Countries so they are no higher than 25% of the developed world price.
And it will place over 500 granted patents and over 300 pending applications (relating to approximately 80 patent families) in a pool to help others to develop potential medicines for neglected diseases.
It is planning to reinvest 20% of profits made from sales of medicines in the Least Developed Countries to support strengthening of healthcare infrastructure.
GSK also reported a substantive increase in its level of charitable support. <헬스코리아뉴스>